Company intelligence / Profile preview

Elixirgen

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Early clinical data published in NEJM Evidence demonstrated the first-ever successful sustained telomere elongation in two EXG-34217-treated patients with Telomere Biology Disorder, with no treatment-related safety concerns observed over a 24-month and 5-month period after EXG-34217 infusion. Preclinical data demonstrated restoration of muscular function in DMD model mice with no safety findings.

Therapeutic areas: HematologyOtherInfectious DiseasesPulmonologyRare Diseases
Modalities: mRNA-based drugsStem cell therapyGene therapyCell therapyVaccine
Industry: Biotech

Partnerships

Ricoh Co., Ltd.Hitachi Global Life SolutionsCincinnati Children's Hospital Medical Center

Beyond the preview

Go deeper on Elixirgen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elixirgen.

Explore the full profile